Search

This week, we bring you an interview with Dr. Richard Alm, Alliance Director at CARB-X, a major current funder of new antimicrobials, including phage! Richard shares how he sees phages fitting into the clinical landscape, and shares his adv

For this week's feature article, Dr. Rohit Kongari interviewed Dr. Ben Burrowes, Senior Scientist at the Center for Phage Technology at Texas A&M University, about his path from phage PhD to industry scientist, to running his own consultanc

Since 2003, Denise Tremblay has managed the phage collection at the Félix d'Hérelle Reference Center for Bacterial Viruses at the Université Laval in Quebec City, Canada. We interviewed Denise about how the center collects, stores and distr

The last time we were at a conference, it was Phage Futures Congress 2020 (Feb 5-6, 2020). Since we're all working from home, it's a perfect time to reflect back on the phage development community's recent progress. In attending this year's

This week, we bring you an interview with Danish Malik, Senior Lecturer at Loughborough University. He tells us about current challenges with phage manufacturing, including what phage companies need to think about, and how academic-commerci

This week, we bring you an interview with Michele Wales, founder of the legal firm InHouse Patent Counsel. She tells us about the unique challenges phage companies face in protecting their IP, and why she's optimistic about what's to come.

Last Fall, we attended the Phage Futures Europe conference, which covered phage commercialization with a focus on how European regulators are thinking about phage therapy. This week, we present our full recap of that event, just in time to

This week, Milan Buňata of MB Pharma, a Czech company that's recently gotten into phage, tells us about phage therapy traditions in the Czech Republic, what their company is working toward, and their interest in collaborating with the phage

NCTC, a culture collection that supplies bacterial strains around the world, is re-launching its phage collection. How did this come about, and what does this mean for the phage community? We interviewed a group of NCTC microbiologists to f

We attended Phage Futures 2019 at the end of January, and now present our full recap of the event. The first annual Phage Futures Congress, hosted by Kisaco Research, was held in Washington, DC from January 29-30, 2019. The event brought in

A look into government incentives for antimicrobial development, and how they apply to phage therapeutic development. If phage therapeutics are going to be developed as drugs, at least in the US, there needs to be significantly more investm

In past issues, we covered what it means to patent something & whether patenting works for phages. In this issue, we dive into an alternative to patenting: trade secrecy. In past issues, we covered what it means to patent something and whet

Simply having a patent on something doesn’t actually protect your invention. That patent has to actually hold up in court. How is this determined, and what kind of chance do phages stand? Simply having a patent on something doesn’t actually

You may have heard through the grapevine that “phages can’t be patented”, but several phage patents exist, and biotech and pharma are investing in phage-based therapeutics. What’s the deal? You may have heard through the grapevine that “pha

This week, we bring you a Q&A with BiomX CBO Assaf Oron. This week, we bring you a Q&A with BiomX CBO Assaf Oron. BiomX is a biotech company commercializing a platform for using phages as tools to eradicate bacteria associated with chronic